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Abstract 
Oral-transmucosal (OTM) drug delivery refers to noninvasive and painless administration of medical 
preparations through any oral cavity membrane to achieve systemic effects (Sattar et al., 2014). 
Regarding sedative drugs, OTM administration is very attractive in veterinary medicine, especially for 
patients difficult to inject and restrain (Messenger et al., 2016). This study aims to compare the 
pharmacokinetics of dexmedetomidine after OTM and intramuscular (IM) administration combined 
with methadone. After obtaining Ethical Committee approval and owner’s written consent, eight 
dogs, were administered with dexmedetomidine (10 g/kg) and methadone (0.4 mg/kg) by OTM and 
other 4 dogs by IM route. Blood samples were collected at prefixed times up to four hours. 
Dexmedetomidine was quantified by a validated HPLC-MS method. On dexmedetomidine 
concentrations, a pharmacokinetic analysis was carried out with a noncompartmental approach 
(Phoenix WinNonlin® 7.0, Pharsight, Cary, NC). Mean ± SD terminal half-lives of dexmedetomidine 
were 187.42 ± 109.66 and 94.78 ± 34.08 min after OTM and IM administration, respectively. Maximum 
serum (Cmax) concentrations were 0.83 ± 0.32 and 9.09 ± 2.46 ng/mL for OTM and IM administration, 
respectively. Time to maximum concentration (Tmax) were 44.38 ± 32.16 and 21.25±11.39 min by OTM 
and IM administration, respectively. Area under the curve from 0 to the last measured concentration 
(AUClast) were 103.75 ± 30.23 and 614.87 ± 77.15 min*ng/mL for OTM and IM administration, 
respectively. Cmax, Tmax and AUClast values by OTM route demonstrate a lower and delayed 
absorption of the drug compared to IM. To complete the study, the pharmacokinetic analysis of 
methadone is foreseen, so as a clinical trial to compare the clinical effects of the combination of 
dexmedetomidine and methadone by OTM and IM administration and to establish an effective dosage 
of oral-transumucosal route in dogs for this association. 
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